TOLAZOLINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C10H12N2
Molecular Weight	160.2157
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C(C1=NCCN1)C2=CC=CC=C2

InChI

InChIKey=JIVZKJJQOZQXQB-UHFFFAOYSA-N

InChI=1S/C10H12N2/c1-2-4-9(5-3-1)8-10-11-6-7-12-10/h1-5H,6-8H2,(H,11,12)

HIDE SMILES / InChI

Molecular Formula	C10H12N2
Molecular Weight	160.2157
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugs.com/pro/priscoline.html | https://www.ncbi.nlm.nih.gov/pubmed/8487790

Tolazoline, also known as priscoline, was used in treatment of persistent pulmonary hypertension of the newborn. But that prescription was discontinued. Priscoline given intravenously produces vasodilatation, primarily due to a direct effect on vascular smooth muscle, and cardiac stimulation; the blood pressure response depends on the relative contributions of the two effects. Priscoline usually reduces pulmonary arterial pressure and vascular resistance. The mechanisms of its therapeutic effects are not clear, but is known, that tolazoline is a non-selective competitive α-adrenergic receptor antagonist and it possesses histamine agonist activity.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor alpha-1 171 Target ID: CHEMBL2094251 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11938943	Antagonist 2849
Histamine H1 receptor 316 Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8487790	Agonist 2752
Histamine H2 receptor 46 Target ID: CHEMBL1941 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8487790	Agonist 2752

Conditions

Condition	Modality	Targets	Highest Phase	Product
Persistent pulmonary hypertension of the newborn 3 Sources: https://www.drugs.com/pro/priscoline.html	Primary		Approved 8583	PRISCOLINE Approved Use Unknown Launch Date 1948

C_max

Value	Dose	Co-administered	Analyte	Population
3.8 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3576663	3.2 mg single, intravenous dose: 3.2 mg route of administration: Intravenous experiment type: SINGLE co-administered:		TOLAZOLINE blood	Homo sapiens population: UNHEALTHY age: NEWBORN sex: FEMALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.15 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3576663	3.2 mg single, intravenous dose: 3.2 mg route of administration: Intravenous experiment type: SINGLE co-administered:		TOLAZOLINE blood	Homo sapiens population: UNHEALTHY age: NEWBORN sex: FEMALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
2 mg/kg single, intravenous Highest studied dose Dose: 2 mg/kg Route: intravenous Route: single Dose: 2 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/6970261	unhealthy, 36 weeks Health Status: unhealthy Age Group: 36 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/6970261	Other AEs: Erythema, Thrombocytopenia... Other AEs: Erythema (60%) Thrombocytopenia (45%) Hyponatremia (40%) Gastric acid increased (36%) Seizures (30%) Hematuria (23%) Hypotension (19%) Oliguria (11%) Abdominal distension (9%) Activity motor exaggerated (6%) Tracheal bleeding (6%) Sources: https://pubmed.ncbi.nlm.nih.gov/6970261

AEs

AE	Significance	Dose	Population
Oliguria	11%	2 mg/kg single, intravenous Highest studied dose Dose: 2 mg/kg Route: intravenous Route: single Dose: 2 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/6970261	unhealthy, 36 weeks Health Status: unhealthy Age Group: 36 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/6970261
Hypotension	19%	2 mg/kg single, intravenous Highest studied dose Dose: 2 mg/kg Route: intravenous Route: single Dose: 2 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/6970261	unhealthy, 36 weeks Health Status: unhealthy Age Group: 36 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/6970261
Hematuria	23%	2 mg/kg single, intravenous Highest studied dose Dose: 2 mg/kg Route: intravenous Route: single Dose: 2 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/6970261	unhealthy, 36 weeks Health Status: unhealthy Age Group: 36 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/6970261
Seizures	30%	2 mg/kg single, intravenous Highest studied dose Dose: 2 mg/kg Route: intravenous Route: single Dose: 2 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/6970261	unhealthy, 36 weeks Health Status: unhealthy Age Group: 36 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/6970261
Gastric acid increased	36%	2 mg/kg single, intravenous Highest studied dose Dose: 2 mg/kg Route: intravenous Route: single Dose: 2 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/6970261	unhealthy, 36 weeks Health Status: unhealthy Age Group: 36 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/6970261
Hyponatremia	40%	2 mg/kg single, intravenous Highest studied dose Dose: 2 mg/kg Route: intravenous Route: single Dose: 2 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/6970261	unhealthy, 36 weeks Health Status: unhealthy Age Group: 36 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/6970261
Thrombocytopenia	45%	2 mg/kg single, intravenous Highest studied dose Dose: 2 mg/kg Route: intravenous Route: single Dose: 2 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/6970261	unhealthy, 36 weeks Health Status: unhealthy Age Group: 36 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/6970261
Activity motor exaggerated	6%	2 mg/kg single, intravenous Highest studied dose Dose: 2 mg/kg Route: intravenous Route: single Dose: 2 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/6970261	unhealthy, 36 weeks Health Status: unhealthy Age Group: 36 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/6970261
Tracheal bleeding	6%	2 mg/kg single, intravenous Highest studied dose Dose: 2 mg/kg Route: intravenous Route: single Dose: 2 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/6970261	unhealthy, 36 weeks Health Status: unhealthy Age Group: 36 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/6970261
Erythema	60%	2 mg/kg single, intravenous Highest studied dose Dose: 2 mg/kg Route: intravenous Route: single Dose: 2 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/6970261	unhealthy, 36 weeks Health Status: unhealthy Age Group: 36 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/6970261
Abdominal distension	9%	2 mg/kg single, intravenous Highest studied dose Dose: 2 mg/kg Route: intravenous Route: single Dose: 2 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/6970261	unhealthy, 36 weeks Health Status: unhealthy Age Group: 36 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/6970261

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
Ca2+ channels 59

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
Ca2+ channels 62	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/1983153/	likely

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY562109	https://www.001chemical.com/chem/59-98-3
3B Scientific (Wuhan) Corp	3B2-1620	http://www.3bsc.com/index/pro_info.php?id=55336
AA Blocks	AA00E8O3	http://www.aablocks.com/goods/Goods/detail?id=AA00E8O3
Aaron Chemicals	AR00E9FV	http://www.aaronchem.com/59-98-3
abcr GmbH	AB331678	http://www.abcr.com/shop/en/AB331678
Achemica	ACMC-209mh8	http://www.achemica.com/prodinfo/?id=129496
AEchem Scientific Corp., USA	AE026734	http://www.aechemsc.com/info_products/AE026734.php
AHH Chemical co.,ltd	MT-59558	http://www.ahhchemical.com/product/MT-59558.html
AK Scientific, Inc. (AKSCI)	67867	http://www.aksci.com/item_detail.php?cat=67867
Anward	ANW-33402	http://www.anward.com/pro_result/5475
Ark Pharma Scientific Limited	H-002242	http://www.arkpharmtech.com/product/7297.html
AstaTech, Inc.	FD7203	http://www.astatechinc.com/CPSResult.php?CRNO=37292
Aurora Fine Chemicals LLC	A00.762.267	http://online.aurorafinechemicals.com/info?ID=A00.762.267
BLD Pharm	BD154330	http://www.bldpharm.com/products/59-98-3.html
Chem Scene	CS-3181	http://www.chemscene.com/59-98-3.html
ChemMol	49416425	http://www.chemmol.com/chemmol/49416425.html
ChemMol	49416427	http://www.chemmol.com/chemmol/49416427.html
ChemMol	99115266	http://www.chemmol.com/chemmol/99115266.html
Chemspace	CSSB00011215504	https://chem-space.com/CSSB00011215504
CSNpharm	CSN12104	https://www.csnpharm.com/products/tolazoline.html
DC Chemicals	DC31889	http://www.dcchemicals.com//product_show-Tolazoline.html
Debye Scientific	DB-053506	http://www.debyesci.com/cas_59-98-3.html
eNovation Chemicals	K09775	http://www.enovationchem.com/productDetails.asp?productID=K09775
eNovation Chemicals	Y0978225	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0978225
Finetech	FT-0603251	http://www.finetechnology-ind.com/prod/detail/pub/59-98-3.html
Glentham Life Sciences	GL5593	http://www.glentham.com/products/product/GL5593/
Hairui	HR140028	http://www.hairuichem.com/en/product/59-98-3.html
Lab Network	LN00246265	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00246265
Matrix Scientific	204596	https://www.matrixscientific.com/204596.html
mcule	MCULE-5694308124	https://mcule.com/MCULE-5694308124/
MedChem Express	HY-A0066	https://www.medchemexpress.com/tolazoline.html
Molcore	MC562109	https://www.molcore.com/product/59-98-3
MuseChem	I004252	https://www.musechem.com/product/I004252.html
Oakwood	336858	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=165581&ExtHyperLink=1
OChem	11944	http://www.ocheminc.com/index.php?act=psearch&pid=059T983
Parchem	30162	http://www.parchem.com/chemical-supplier-distributor/Tolazoline-020162.aspx
Sigma-Aldrich	293490_ALDRICH	https://www.sigmaaldrich.com/catalog/product/aldrich/293490?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S545537	http://www.smolecule.com/products/s545537
Smolecule	S772617	https://www.smolecule.com/products/s772617
TCI (Tokyo Chemical Industry)	B3806	http://www.tcichemicals.com/eshop/en/us/commodity/B3806/index.html
THE BioTek	bt-285913	https://www.thebiotek.com/product/inhibitors/bt-285913
Yuhao Chemical	YH09263	http://www.chemyuhao.com/59-98-3.html

PubMed

Title	Date	PubMed
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.	2011-07-14	21599003
Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study.	2010-08	19900936
Cardiovascular effects of sub-daily levels of ambient fine particles: a systematic review.	2010-06-15	20550697
Functional and pharmacological characterization of a beta-adrenergic-like octopamine receptor from the silkworm Bombyx mori.	2010-06	20417278
Pharmacological characterization of a Bombyx mori alpha-adrenergic-like octopamine receptor stably expressed in a mammalian cell line.	2010-02	19918790
Adverse drug effects in hospitalized elderly: data from the healthcare cost and utilization project.	2010	22291486
Bench-to-bedside review: carbon dioxide.	2010	20497620
Adenosine and adenosine receptors: Newer therapeutic perspective.	2009-06	20442815
Accurate localization of life threatening colonic hemorrhage during nuclear medicine bleeding scan as an aid to selective angiography.	2009-05-27	19580686
Butorphanol-azaperone-medetomidine for immobilization of captive white-tailed deer.	2009-04	19395755
Physiologic effects of nasal oxygen or medical air administered prior to and during carfentanil-xylazine anesthesia in North American elk (Cervus canadensis manitobensis).	2009-03	19368239
A novel approach for percutaneous treatment of massive nonocclusive mesenteric ischemia: tolazoline and glycerol trinitrate as effective local vasodilators.	2009-02-01	19156878
The clinical outcomes of transcatheter microcoil embolization in patients with active lower gastrointestinal bleeding in the small bowel.	2009-01-14	19568468
A novel high-throughput screening assay for putative antidiabetic agents through PPARalpha interactions.	2008-10	18812576
Evaluation of intramuscular butorphanol, azaperone, and medetomidine and nasal oxygen insufflation for the chemical immobilization of white-tailed deer, Odocoileus virginianus.	2008-09	18817017
Effect of vasoactive agents on the dermatopharmacokinetics and systemic disposition of model compounds, salicylate and FITC-dextran 4 kDa, following intracutaneous injection of the compounds.	2008-05-22	18294788
A comparison of two combinations of xylazine-ketamine administered intramuscularly to alpacas and of reversal with tolazoline.	2008-05	18282257
A diazonium ion cascade from the nitrosation of tolazoline, an imidazoline-containing drug.	2008-02	18247523
Nucleoside and DNA adducts from N-nitrosotolazoline.	2008-02	18232662
N-nitrosotolazoline: decomposition studies of a typical N-nitrosoimidazoline.	2008-02	18232661
Castration of lambs: a welfare comparison of different castration techniques in lambs over 10 weeks of age.	2007-05	16527503
Impaired cognition and attention in adults: pharmacological management strategies.	2007-02	19300541
Antagonism by imidazoline-type drugs of muscarinic and other receptors in the guinea-pig ileum.	2006-07	16879492
Reported medication use in the neonatal intensive care unit: data from a large national data set.	2006-06	16740839
Antagonism of detomidine sedation in the horse using intravenous tolazoline or atipamezole.	2006-05	16706278
Comparative effects of tolazoline and nitroprusside on human isolated radial artery.	2006-01	16368348
Persistent pulmonary hypertension of the newborn: pathogenesis, etiology, and management.	2006	16774297
Clinical assessment of epidural analgesia induced by xylazine-lidocaine combination accompanied by xylazine sedation in calves.	2005-10-01	21851664
Ergotamine-induced upper extremity ischemia: a case report.	2005-06-22	15968153
Pulmonary hypertension in the newborn.	2005-06	15911456
Prevention and management of meconium aspiration syndrome--assessment of evidence based practice.	2005-05	15731907
Bench-to-bedside review: Ventilator strategies to reduce lung injury -- lessons from pediatric and neonatal intensive care.	2005-04	15774075
2-(Anilino)imidazolines and 2-(benzyl)imidazoline derivatives as h5-HT1D serotonin receptor ligands.	2004-09-20	15324890
Effectiveness of antagonists for tiletamine-zolazepam/xylazine immobilization in female white-tailed deer.	2004-07	15465721
Persistent pulmonary hypertension of the newborn.	2004-06	15195195
A comparison of two intramuscular doses of xylazine-ketamine combination and tolazoline reversal in llamas.	2004-04	15053746
Clinically diagnosed nonocclusive mesenteric ischemia after cardiopulmonary bypass: retrospective study.	2004-03	15248641
An in vitro study of the effects of Cassia podocarpa fruit on the intestinal motility of rats.	2004-02	15070180
The effect of different combinations of lignocaine, ketoprofen, xylazine and tolazoline on the acute cortisol response to dehorning in calves.	2003-10	16032330
Inhaled nitric oxide applications in paediatric practice.	2002-01	22368608
Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding.	1998-04-01	9605427
Spasms of the hepatic artery following percutaneous transluminal angioplasty and tolazoline administration in a liver transplant patient.	1996-05-01	8661646
Effects of tolazoline and prostacyclin on pulmonary hypertension in infants after cardiac surgery.	1992-09	1521438
Blood flow distribution and brain metabolism during tolazoline-induced hypotension in newborn dogs.	1990-08	2395600
Bolus and continuous infusion of tolazoline in neonates with hypoxemia.	1986	3486756
[Renal disorders in the newborn infant].	1984-01-01	6397726
[Tolazoline and dopamine in the treatment of the persistent fetal circulation syndrome].	1983-10	6646141
Tolazoline and acute renal failure in the newborn.	1981-05-30	6112562
Hypochloremic metabolic alkalosis following tolazoline-induced gastric hypersecretion.	1980-02	7354974
DDT-induced myoclonus: serotonin and alpha noradrenergic interaction.	1979-02	37558

Patents

Sample Use Guides

In Vivo Use Guide

An initial dose of 1 to 2 mg/kg, via scalp vein, followed by an infusion of 1 to 2 mg/kg per hour have usually resulted in significant increases in arterial oxygen. There is very little experience with infusions lasting beyond 36 to 48 hours. Response, if it occurs, can be expected within 30 minutes after the initial dose.

Route of Administration: Intravenous

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:33:24 GMT 2025` Edited by `admin` on `Mon Mar 31 18:33:24 GMT 2025`
Record UNII	CHH9H12AQ3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TOLAZOLINE

Official Name

English

TOLAZINE

Preferred Name

English

TOLAZOLINE [VANDF]

Common Name

English

Tolazoline [WHO-DD]

Common Name

English

NSC-35110

Code

English

tolazoline [INN]

Common Name

English

TOLAZOLINE [MI]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QM02AX02